Literature DB >> 9090523

Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene.

R Myerowitz1.   

Abstract

Tay-Sachs disease is an autosomal recessive disorder affecting the central nervous system. The disorder results from mutations in the gene encoding the alpha-subunit of beta-hexosaminidase A, a lysosomal enzyme composed of alpha and beta polypeptides. Seventy-eight mutations in the Hex A gene have been described and include 65 single base substitutions, one large and 10 small deletions, and two small insertions. Because these mutations cripple the catalytic activity of beta-hexosaminidase to varying degrees, Tay-Sachs disease displays clinical heterogeneity. Forty-five of the single base substitutions cause missense mutations; 39 of these are disease causing, three are benign but cause a change in phenotype, and three are neutral polymorphisms. Six nonsense mutations and 14 splice site lesions result from single base substitutions, and all but one of the splice site lesions cause a severe form of Tay-Sachs disease. Eight frameshift mutations arise from six deletion- and two insertion-type lesions. One of these insertions, consisting of four bases within exon 11, is found in 80% of the carriers of Tay-Sachs disease from the Ashkenazi Jewish population, an ethnic group that has a 10-fold higher gene frequency for a severe form of the disorder than the general population. A very large deletion, 7.5 kilobases, including all of exon 1 and portions of DNA upstream and downstream from that exon, is the major mutation found in Tay-Sachs disease carriers from the French Canadian population, a geographic isolate displaying an elevated carrier frequency. Most of the other mutations are confined to single pedigrees. Identification of these mutations has permitted more accurate carrier information, prenatal diagnosis, and disease prognosis. In conjunction with a precise tertiary structure of the enzyme, these mutations could be used to gain insight into the structure-function relationships of the lysosomal enzyme.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090523     DOI: 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  19 in total

1.  Expression, purification, crystallization and preliminary crystallographic analysis of a GH20 β-N-acetylglucosaminidase from the marine bacterium Vibrio harveyi.

Authors:  Piyanat Meekrathok; Marco Bürger; Arthur T Porfetye; Ingrid R Vetter; Wipa Suginta
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

2.  Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease.

Authors:  Karolina M Stepien; Su Han Lum; J Edmond Wraith; Christian J Hendriksz; Heather J Church; David Priestman; Frances M Platt; Simon Jones; Ana Jovanovic; Robert Wynn
Journal:  JIMD Rep       Date:  2017-12-07

Review 3.  Nonsense-mediated decay in genetic disease: friend or foe?

Authors:  Jake N Miller; David A Pearce
Journal:  Mutat Res Rev Mutat Res       Date:  2014-05-28       Impact factor: 5.657

4.  The p.L302P mutation in the lysosomal enzyme gene SMPD1 is a risk factor for Parkinson disease.

Authors:  Ziv Gan-Or; Laurie J Ozelius; Anat Bar-Shira; Rachel Saunders-Pullman; Anat Mirelman; Ruth Kornreich; Mali Gana-Weisz; Deborah Raymond; Liron Rozenkrantz; Andres Deik; Tanya Gurevich; Susan J Gross; Nicole Schreiber-Agus; Nir Giladi; Susan B Bressman; Avi Orr-Urtreger
Journal:  Neurology       Date:  2013-03-27       Impact factor: 9.910

5.  Novel β-N-acetylglucosaminidases from Vibrio harveyi 650: cloning, expression, enzymatic properties, and subsite identification.

Authors:  Wipa Suginta; Duangkamon Chuenark; Mamiko Mizuhara; Tamo Fukamizo
Journal:  BMC Biochem       Date:  2010-09-29       Impact factor: 4.059

6.  SNP analysis using CataCleave probes.

Authors:  John J Harvey; Steven R Brant; Jay R Knutson; Myun K Han
Journal:  J Clin Lab Anal       Date:  2008       Impact factor: 2.352

7.  Expanding rare disease drug trials based on shared molecular etiology.

Authors:  Philip J Brooks; Danilo A Tagle; Steve Groft
Journal:  Nat Biotechnol       Date:  2014-06       Impact factor: 54.908

8.  Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease.

Authors:  Allison M Bradbury; Heather L Gray-Edwards; Jamie L Shirley; Victoria J McCurdy; Alexandria N Colaco; Ashley N Randle; Pete W Christopherson; Allison C Bird; Aime K Johnson; Diane U Wilson; Judith A Hudson; Nicholas L De Pompa; Donald C Sorjonen; Brandon L Brunson; Mylvaganam Jeyakumar; Frances M Platt; Henry J Baker; Nancy R Cox; Miguel Sena-Esteves; Douglas R Martin
Journal:  Exp Neurol       Date:  2014-10-05       Impact factor: 5.330

9.  Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor.

Authors:  Mazal Karpati; Ephraim Gazit; Boleslaw Goldman; Amos Frisch; Roberto Colombo; Leah Peleg
Journal:  Neurogenetics       Date:  2003-11-27       Impact factor: 2.660

10.  Patient-Derived Phenotypic High-Throughput Assay to Identify Small Molecules Restoring Lysosomal Function in Tay-Sachs Disease.

Authors:  Dennis J Colussi; Marlene A Jacobson
Journal:  SLAS Discov       Date:  2019-01-07       Impact factor: 3.341

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.